

AWARD NUMBER: W81XWH-18-1-0499

TITLE: Rare Variants in Systemic Sclerosis

PRINCIPAL INVESTIGATOR: Brendan Lee

CONTRACTING ORGANIZATION: Baylor College of Medicine  
Houston, Texas 77030-3411

REPORT DATE: SEPTEMBER 2019

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Development Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

# REPORT DOCUMENTATION PAGE

*Form Approved*  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

<b>1. REPORT DATE</b> SEPTEMBER 2019			<b>2. REPORT TYPE</b> ANNUAL TECHNICAL		<b>3. DATES COVERED</b> August 15, 2018 - August 14, 2019	
<b>4. TITLE AND SUBTITLE</b> RARE VARIANTS IN SYSTEMIC SCLEROSIS					W81XWH-18-1-0499	
					<b>5b. GRANT NUMBER</b> GRANT12507060	
					<b>5c. PROGRAM ELEMENT NUMBER</b>	
<b>6. AUTHOR(S)</b> Brendan Lee, MD, PhD  E-Mail: blee@bcm.edu					<b>5d. PROJECT NUMBER</b>	
					<b>5e. TASK NUMBER</b>	
					<b>5f. WORK UNIT NUMBER</b>	
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> Baylor College of Medicine One Baylor Plaza Houston, Texas 77030-3411					<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b>  U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012					<b>10. SPONSOR/MONITOR'S ACRONYM(S)</b>	
					<b>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</b>	
<b>12. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for Public Release; Distribution Unlimited						
<b>13. SUPPLEMENTARY NOTES</b>						
<b>14. ABSTRACT</b> Systemic Sclerosis (SSc, scleroderma) has considerable morbidity and the highest mortality of all the systemic autoimmune diseases. The cause(s) of SSc is/are unknown and it is generally considered to result from a combination of external triggers operating in the context of genetic susceptibility, similar to other complex genetic autoimmune diseases. The genetic component has been estimated to contribute 30% to the risk of developing SSc. The overall goal of this project is to identify rare genetic variants, that increase susceptibility to SSc and that influence clinical outcomes. Metabolic pathways influenced by these variants will provide insight into pathogenetic mechanisms of this and other fibrotic diseases, leading to novel therapeutic approaches. This study is on track for completion of the largest whole genome sequencing (WGS) project in scleroderma. The samples are submitted for sequencing and data are eagerly anticipated along with analysis and genotype/phenotype correlations.						
<b>15. SUBJECT TERMS</b>  Systemic Sclerosis, Scleroderma, Whole Genome Sequencing (WGS), genetic variants, rare variants.						
<b>16. SECURITY CLASSIFICATION OF:</b>			<b>17. LIMITATION OF ABSTRACT</b>	<b>18. NUMBER OF PAGES</b>	<b>19a. NAME OF RESPONSIBLE PERSON</b>	
<b>a. REPORT</b>  Unclassified	<b>b. ABSTRACT</b>  Unclassified	<b>c. THIS PAGE</b>  Unclassified	Unclassified	11	<b>19b. TELEPHONE NUMBER</b> <i>(include area code)</i>	

Standard Form 298 (Rev. 8-98)  
Prescribed by ANSI Std. Z39.18

## TABLE OF CONTENTS

1. <b>INTRODUCTION</b>	4
2. <b>KEYWORDS</b>	4
3. <b>ACCOMPLISHMENTS</b>	4-6
a. What were the major goals of the project?	4
b. What was accomplished under these goals?	5
c. What opportunities for training and professional development has the project provided?	6
d. How were the results disseminated to communities of interest?	6
e. What do you plan to do during the next reporting period to accomplish the goals?	6
4. <b>IMPACT</b>	6
a. What was the impact on the development of the principal discipline of the project?	6
b. What was the impact on other disciplines?	6
c. What was the impact on technology transfer?	6
d. What was the impact on society beyond science and technology?	6
5. <b>CHANGES/PROBLEMS</b>	6-7
a. Changes in approach and reasons for change	6
b. Actual or anticipated problems or delays and action or plans to resolve them	7
c. Changes that had a significant impact on expenditures	7
d. Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents	7
e. Significant changes in use or care of human subjects	7
f. Significant changes in use or care of vertebrate animals	7
g. Significant changes in use of biohazards and/or select agents	7
6. <b>PRODUCTS</b>	7
a. Publications, conference papers, and presentations	7
i. Journal publications, Books or other non-periodical, one-time publications and other publications, conference papers, presentations	7
ii. Website(s) or other Internet site(s)	7
iii. Technology or techniques	7
iv. Inventions, patent applications, and/or licenses	7
v. Other products	7
7. <b>PARTICIPANTS &amp; OTHER CALLORATING ORGANIZATIONS</b>	7-10
a. What individuals have worked on the project?	7-10
b. Has there been a change in the active other support of the PD/PI(s) or Senior/key personnel since the last reporting period?	10
c. What other organizations were involved as partners?	10-11
8. <b>SPECIAL REPORTING REQUIREMENTS</b>	11
9. <b>APPENDICES</b>	11

1. **INTRODUCTION:** The subject/topic area of this research is Systemic Sclerosis (SSc, Scleroderma). The purpose of the research is to identify genetic variants that contribute to SSc disease susceptibility and influence outcome. The approach involves whole genome sequencing of 100 trios (300 individuals including affected case and both parents). Previous Genome-Wide-Association-Studies (GWAS) have identified gene regions that are associated with disease but the majority of these are in non-coding areas so the impact of these variants is unclear. This study will identify rare variants (both inherited and de novo mutations) and will analyze these mutations according to the role they likely play in disease pathogenesis. The immediate outcome of this project will be identification of the causal variants in multiple pathways associated with SSc susceptibility with the long-range impact will be the identification of the role these variants play in disease causation and severity/outcome.
2. **KEYWORDS:** Systemic Sclerosis, Scleroderma, Whole Genome Sequencing (WGS), genetic variants, rare variants.
3. **OVERALL PROJECT SUMMARY:** This study is on track for completion of the largest whole genome sequencing (WGS) project in scleroderma. The samples have been submitted for sequencing and quality control procedures have been done requiring the replacement of DNA from 2 individuals. Data are eagerly anticipated in this coming year along with analysis and genotype/phenotype correlations.
4. **ACCOMPLISHMENTS:**
  - **What were the major goals of the project?**
    - Task 1: Institutional Review Board (IRB) and DOD Human Research Protection Office (HRPO) approval. Timeline months 1-6 (15 Aug 2018 – 14 Jan 2019); actually HRPO approval was received later than expected on 11 Jul 2019 due to a miscommunication– but this has been resolved..
      - UT Houston IRB approval was obtained previously under the general approval for the genetics studies in SSc; a notice was sent to the IRB and accepted as a defined sub-study with the most recent annual reviews up-to-date as of 22 Jan 2019; so **completed**.
      - Baylor College of Medicine: Whole genome sequencing will catalog the largest amount of genetic variation in scleroderma cases and will provide information on noncoding and rare variation. The incorporation of whole genome generated information in analyses of complex traits is an emerging tool for defining underlying genetic underpinnings. The sequencing and processing will be completed at the Baylor Human Genome Sequencing Center and data analysis in the lab of Dr Brendan Lee. The generated data will be the basis of the proposed work.
      - HRPO approval was received 11 Jul 2019 (HRPO Log Number E00551.1a) so **completed**.
    - Task 2: Prioritization, preparation and distribution of samples to be sent to BCM for genotyping: Timeline months 7- 8 (15 Feb 2019 – 14 Apr 2019)

- Samples were identified on the basis of protocol-defined criteria and prepared for shipping during this time and were subsequently sent to BCM. So **completed**.
  - Task 3: Sequencing of 300 samples with appropriate quality control measures: Timeline months 9-18 (15 Apr 2019 – 14 Feb 2020)
    - All samples were sent to BCM for whole genome sequencing; of the samples sent 2 failed quality control measures and new replacement aliquots were prepared and sent to BCM on 19 Aug 2019. So **underway and on schedule**.
  - Task 4: Processing, including imputation using the generated sequence data. Timeline months 19-21 (15 Feb 2020 – 14 May 2020). **Awaiting data** from Task 3.
  - Task 5: Data analysis and prioritization of candidates for validation in other, future cohorts. Timeline months 22-36 (15 May 2020 – 14 Aug 2021). **Awaiting data** from Task 4.
  - Task 6: Association analysis of the most likely identified variants with clinical disease features. Timeline months 34-36 (15 May 2021 – 14 Aug 2012). **Awaiting data** from Tasks 3 and 4.
  - Task 7: Preparation of manuscripts for publication. Timeline months 34-36 (15 May 2021– 14 Aug 2021). **Awaiting data** from Task 6.
  - Task 8: Quarterly meetings between the UT-H and BCM teams to coordinate all aspects of the project and review and interpret data as it becomes available. Timeline months 3-36 (15 Nov 2019 – 14 Aug 2021). **Ongoing**.
    - We have had 2 face-to-face meetings and 2 conference calls involving both teams for a total of 4 meetings since the study started. We are up-to-date on these and plan to continue to meet on a regular basis – at least quarterly or more frequently as the data become available.
- **What was accomplished under these goals?**
- Tasks 1 and 2 have been completed and Task 3 is well underway with sequencing data expected to be complete on-time or even ahead of schedule. The analysis and interpretation phases are expected to be quite time-consuming so generating the sequence data ahead of schedule will be welcome. Task 8 (quarterly meetings of the UT-H and BCM teams) is ongoing as scheduled.
  - BCM side of Task 2: Quality checking and trio family selecting on samples delivered by UT-H Timeline months 9- 10 (15 May 2019 – 14 June 2019)
    - Samples were checked for quality and quantity before final sequencing. Replacements were requested for failed samples. 100 trios were selected based on qualified criteria to initiate the sequencing. Status: **Completed**.

- BCM side of Task 3: Sequencing of 300 samples. Timeline months 11-18 (15 June 2019 – 14 Feb 2020)
        - Replacement samples received to complete the 100 trios whole genome sequencing. Samples were sequenced in batches. Status: **In progress as scheduled.**
  - 
  - **What opportunities for training and professional development has the project provided?**
    - Nothing to report from either institutions.
  - **How were the results disseminated to communities of interest?**
  - Nothing to report from either institutions.
  - **What do you plan to do during the next reporting period to accomplish the goals?**
    - We fully anticipate that the sequence data will have been generated by the next annual report (end of second year = 14 Aug 2020) and analysis well underway (Tasks 3 and 4 anticipated completion 14 May 2020).
    - Additionally, Task 5 evaluation in other cohorts should be initiated.
5. **IMPACT:** *Describe distinctive contributions, major accomplishments, innovations, successes, or any change in practice or behavior that has come about as a result of the project relative to:*
- **What was the impact on the development of the principal discipline(s) of the project?**
    - Nothing to Report.
    - Nothing to Report at this time.
  - **What was the impact on other disciplines?**
    - Nothing to Report.
  - **What was the impact on technology transfer?**
    - Nothing to Report.
  - **What was the impact on society beyond science and technology?**
    - Nothing to Report.
6. **CHANGES/PROBLEMS:** *The Project Director/Principal Investigator (PD/PI) is reminded that the recipient organization is required to obtain prior written approval from the awarding agency Grants Officer whenever there are significant changes in the project or its direction. If not previously reported in writing, provide the following additional information or state, "Nothing to Report," if applicable:*
- **Changes in approach and reasons for change**
    - There have been no changes in approach.

- **Actual or anticipated problems or delays and actions or plans to resolve them**
    - There was a delay in HRPO approval due to a miscommunication, but this was resolved and the project was able to move forward in a timely fashion.
  - **Changes that had a significant impact on expenditures**
    - There were no changes that had a significant impact on expenditures.
  - **Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents**
    - None
  - **Significant changes in use or care of human subjects - None**
  - **Significant changes in use or care of vertebrate animals. None**
  - **Significant changes in use of biohazards and/or select agents None**
7. **PRODUCTS:** *List any products resulting from the project during the reporting period. If there is nothing to report under a particular item, state "Nothing to Report."*
- **Publications, conference papers, and presentations**
    - **Journal publications.** None to date.
    - **Books or other non-periodical, one-time publications.** None to date.
    - **Other publications, conference papers, and presentations.** None to date.
  - **Website(s) or other Internet site(s)**  
None to date.
  - **Technologies or techniques**  
None to date.
  - **Inventions, patent applications, and/or licenses**  
None to date.
  - **Other Products**  
None to date.
8. **PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS**
- **What individuals have worked on the project?**
    - *Provide the following information for: (1) PDs/PIs; and (2) each person who has worked at least one person month per year on the project during the reporting period, regardless of the source of compensation (a person month equals approximately 160 hours of effort). If information is unchanged from a previous submission, provide the name only and indicate "no change."*

Name:	Maureen D. Mayes, MD, MPH (No change from submission)
Project Role:	Principal Investigator; Initiating PI
Researcher Identifier (e.g. ORCID ID):	
Nearest person month worked:	3.0 calendar months
Contribution to Project:	Dr. Mayes is responsible for the overall conduct of the study and for the timely completion of all aspects (Tasks 1 through 8); she supervises UT project personnel and organizes the weekly UT meetings, the quarterly UT-BCM meetings to review progress, potential problems, data collection and results.
Funding Support:	<p><b>New:</b></p> <p>GSK: A multi-centre, randomized, double-blind (sponsor open), placebo-controlled, repeat dose, proof of mechanism study to evaluate the safety, tolerability, pharmacokinetics pharmacodynamics and explore efficacy of GSK2330811 in subjects with diffuse cutaneous systemic sclerosis.</p> <p>Galapagos: Orally administered GLPG1690 for 24 weeks in subjects with systemic sclerosis</p> <p>Eicos: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Intravenous Iloprost in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis</p> <p>University of Michigan: Long-term follow-up of Participants of the Phase II study to evaluate subcutaneous abatacept v. placebo in diffuse cutaneous systemic sclerosis-a double-blind, placebo-controlled, randomized trial (ASSET)</p>

Name:	Dianna Milewicz, MD
Project Role:	Co-Investigator
Researcher Identifier (e.g. ORCID ID):	
Nearest person month worked:	0.6 calendar months
Contribution to Project:	Dr. Milewicz has a strong background in the genetic basis of vascular diseases. Her role to date is that she has provided guidance on study design thus far and in the upcoming years she will advise on the analysis and interpretation of the genetic data. She has served as an advisor on Dr. Mayes' previous scleroderma genetic studies and has worked with the Baylor College of Medicine Genetics group on multiple projects
Funding Support:	<p><b>New:</b></p> <p>NIH/NHLBI: Novel genetic Insight into the molecular pathogenesis</p>

	<p>of atherosclerosis.</p> <p>NIH: Medical Scientist Training Program</p> <p>Texas Heart Institute: Fibromuscular Dysplasia Project</p> <p>Marfan Foundation: Asprosin's Role in Suppressed Appetite and Progeroid Appearance of Marfan Lipodystrophy Syndrome and Neonatal Marfan Syndrome Patients</p> <p>American Heart Association: Molecular Pathogenesis of Occlusive Cerebrovascular Disease Resulting from ACTA2 Mutations</p>
--	--

Name:	Claudia Pedroza, PhD (no change from submission)
Project Role:	Co-Investigator, statistician
Researcher Identifier (e.g. ORCID ID):	
Nearest person month worked:	0.6 calendar months
Contribution to Project:	Dr. Pedroza has been involved in the planning and implementation of the project to date to ensure that data will be interpreted in light of available clinical outcomes.
Funding Support:	No changes

Name:	Patricia Gonzales, LVN (no change from submission)
Project Role:	Project Coordinator
Researcher Identifier (e.g. ORCID ID):	
Nearest person month worked:	3.6 calendar months
Contribution to Project:	Ms Gonzales is responsible for the day-to-day operations of the study, overseeing database queries and reporting to the investigators regarding progress, time lines and review of expenditures.
Funding Support:	

Name:	Julio Charles (no change from submission)
Project Role:	Laboratory Manager
Researcher Identifier (e.g. ORCID ID):	
Nearest person month worked:	3.0 calendar months
Contribution to Project:	Mr Charles is responsible for overseeing the selection, aliquoting and distribution of samples for genotyping and sequencing studies. He coordinates delivery to the Baylor research lab; he attends the weekly lab meetings as well as the project-specific quarterly meetings between the UT and Baylor research groups.
Funding Support:	

Name:	Hau Pham (no change from submission)
Project Role:	Research Assistant
Researcher Identifier (e.g. ORCID ID):	
Nearest person month worked:	3.0 calendar months
Contribution to Project:	Ms. Pham is responsible for the day-to-day work in the Rheumatology Research Lab, to implement sample selection, DNA quantification, DNA measurement and record keeping of samples distributed to Baylor as well as DNA extraction on new samples as needed, and autoantibody determination on these new samples.
Funding Support:	

- **Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?**
  - Ms. Jun Ying, Genetics Data Supervisor at 1.8 calendar months, has left the University as of 6/30/2019 and her position was replaced by Ms. Marka Lyons on 8/16/19.
  - Dr. Shan Chen, Postdoctoral Research Associate (9 Cal Mos) left BCM after the submission of the proposal and right as the grant was funded. Her position was replaced by Dr. Hongzheng Dai.
- **What other organizations were involved as partners?**

#### **BAYLOR COLLEGE OF MEDICINE**

Name:	Brendan Lee, MD, PhD (No change from submission)
Project Role:	Principal Investigator;

Researcher Identifier (e.g. ORCID ID):	
Nearest person month worked:	.30 calendar months
Contribution to Project:	Dr. Lee will be responsible for the overall implementation of the project as well as experiments in all aims. He will be responsible for the overall experimental design, data analysis, implementation, communication, and reporting of the experiments in the grant
Funding Support:	<b>No new support to report since submission</b>

Name:	Lindsay Burrage, MD (No change from submission)
Project Role:	Faculty
Researcher Identifier (e.g. ORCID ID):	
Nearest person month worked:	1.20 calendar months
Contribution to Project:	Dr. Burrage will assist with the overall implementation of the project as well as experiments in all aims. She will also assist with the overall experimental design, data analysis, implementation, communication, and reporting of the experiments in the grant
Funding Support:	<b>No new support to report since submission</b>

Name:	Hongzheng Dai, PhD (replaced Shan Chen from submission)
Project Role:	Research Associate
Researcher Identifier (e.g. ORCID ID):	
Nearest person month worked:	9 calendar months
Contribution to Project:	Dr. Dai will perform data analyses using existing publicly available software and, in addition, write programs to analyze the generated data. She will combine publicly available datasets with the generated data
Funding Support:	<b>No new support to report since submission</b>

## 9. SPECIAL REPORTING REQUIREMENTS

- None

10. **APPENDICES:** Not applicable.